Statins and breast cancer: may matrix metalloproteinase be the missing link

Cancer Investigation

Volumn 27, Issue 4, 2009, Pages 466-470

  Mannello, Ferdinando ^a   Tonti, Gaetana A ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

Breast cancer; Gelatinases; Hmg coa reductase; Matrix metalloproteinases; Statins

Indexed keywords

ATORVASTATIN; CAVEOLIN; CAVEOLIN 1; CHOLESTEROL; COMPACTIN; FLUINDOSTATIN; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE; MEVALONIC ACID; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; ANTINEOPLASTIC AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTEROL BLOOD LEVEL; COLORECTAL CANCER; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; HYDROPHOBICITY; IMMUNOREGULATION; LIPOPHILICITY; LIVER CELL CARCINOMA; METASTASIS; NONHUMAN; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT DURATION; ANIMAL; BREAST TUMOR; ENZYMOLOGY; FEMALE; METABOLISM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHOLESTEROL; DOWN-REGULATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MATRIX METALLOPROTEINASES;

EID: 65249170207     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802491444     Document Type: Review

References (45)

1. Sanchez, C.A.; Rodriguez, E.; Varela, E.; Zapata, E.; Paez, A.; Masso, F.A.; Montafio, L.F.; Loopez-Marure, R. Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress. Cancer Invest 2008, 26, 698-707.
2. Sassano, A.; Platanias, L.C. Statins in tumor suppression. Cancer Lett. 2008,260,11-19.
3. Mannello, F; Tonti, G.A.; Papa, S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Targets 2005, 5, 285-298.
4. Lopez-Otin, C; Matrisian, L.M. Emerging roles of proteases in tumour suppression. Nature Rev Cancer 2007, 7, 800-808.
5. Martin, M.D.; Matrisian, M.L. The other side of MMPs: protective roles in tumor progression. Cancer Metastases Rev. 2007, 26, 717-724.
6. Chabottaux, V.; Noel, A. Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis 2007, 24, 647-656.
7. Goldstein, M.R.; Mascitelli, L.; Pezzetta, F. Cholesterol, statins, and mortality. Lancet 2008, 371,1161.
8. Browing, D.R.; Martin, R.M. Statins and risk of cancer: a systematic review and meta-analysis. Int J Cancer 2008, 120, 833-843.
9. Taylor, M.L.; Wells, B.J.; Smolak, M.J. Statins and cancer: a metaanalysis of case-control studies. Eur J Cancer Prev. 2008,17,259- 268.
10. Solomon, K.R.; Freeman, M.R. Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocr Metab. 2008, 19,113-121.
11. Wang, I.K.; Lin-Shiau, S.Y.; Lin, J.K. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology 2000, 59, 245-254.
12. Vincent, L.; Chen, W.; Hong, L.; Mirshahi, F.; Mishal, Z.; Mirshahi- Khorassani, T.; Vannier, J.P.; Soria, J.; Soria, C. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett 2001, 495, 159-166.
13. Denoyelle, C; Albanese, P.; Uzan, G. Hong, L.; Vannier, J.R; Soria, J.; Soria, C. Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-Coa reductase, on aggressive human breast cancer cells. Cell Signal 2003, 15, 327-338.
14. Thunyakitpisal, P.D.; Chaisuparat, R. Simvastatin, an HMG- CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J Pharmacol Sci. 2004, 94,403-409.
15. Taras, D.; Blanc J.F.; Rullier, A.; Dugot-Senant, N.; Laurendeau, I.; Vidaud, M.; Rosenbaum J. Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J Hepatol. 2007, 46, 69-76.
16. Gauthaman, K.; Richards, M.; Wong, J.; Bongso, A. Comparative evaluation of the effects of statins on human stem and cancer cells in vitro. Reprod Biomed Online 2007, 15, 566-581.
17. Mannello, F. Tonti, G.A.; Bagnara, G.R; Papa, S. Role and function of matrix metalloproteinases in the differentiation and biological characterization of mesenchymal stem cells. Stem Cells 2007,24, 475-481.
18. Wang, C.Y.; Liu, P.Y.; Liao, J.K. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008, 14, 37-44.
19. Vickers, S.; Duncan, C.A.; Vyas, K.P.; Kari, PH.; Arison, B.; Prakash, S.R.; Ramjit, H.G.; Pitzenberger, S.M.; Stokker, G.; Duggan D.E. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG-CoA reductase. Drug Metab Dispos. 1990, 18, 476-483.
20. Halpin, R.A.; Ulm, E.H.; Till, A.E.; Kari, PH.; Vyas, K.R; Hunninghake, D.B.; Duggan, D.E. Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. Drug Metab Dispos. 1993,21,1003-1011.
21. Kieseier, B.C.; Archelos, J.J.; Hartung, H.R Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol. 2004, 61, 929- 932.
22. Neuhaus, O.; Strasser-Fuchs, S.; Fazekas, R; Kieseier, B.C.; Niederwieser, G.; Hartung, H.R; Archelos, J.J. Statins as im- munomodulators: comparison with interferon-beta 1 b in MS. Neurology 2002, 59, 990-997.
23. Turner, N.A.; O'Regan, D.J.; Ball, S.G.; Porter, K.E. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP- 9 mRNA levels. FASEB J. 2005, 19, 804-806.
24. Li, M.; Li, Z.; Sun, X. Statins suppress MMP-2 secretion via inactivation of RhoA/ROCK pathway in pulmonary vascular smooth muscle cells. Eur J Pharmacol. 2008, 591, 219-223.
25. Kumar, A.S.; Benz, C.C.; Shim, V.; Minami, C.A.; Moore, D.H.; Esserman, L.J. Estrogen receptor-negative breast cancer is less likely arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev. 2008, 17,1028-1033.
26. Kwan, M.L.; Habel, LA.; Flick, E.D.; Quesenberry, CP; Caan, B. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat. 2008, 109, 573-579.
27. Byers, T. Statins, breast cancer, and an invisible switch? Cancer Epidemiol Biomarkers Prev. 2008, 17,1026-1027.
28. Cariati, M.; Purushotham, A.D. Stem cells and breast cancer. Histopathology 2008, 52, 99-107.
29. Sotgia, R; Rui, H.; Bonuccelli, G.; Mercier, I.; Pestell, R.G.; Lisanti, M.R Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers. Cancer Res. 2006, 66,10647-10651.
30. Elsheikh, S.E.; Green, A.R.; Rakha, E.A.; Samaka, R.M.; Ammar, A.A.; Powe, D.; Reis-Filho, J.S.; Ellis, I.O. Caveolin 1 and caveolin 2 are associated with breast cancer basal-like and triple negative immunophenotype. Br J Cancer 2008, 99, 327-334.
31. Schlegel, A.; Lisanti, M.R The caveolin triad: caveolae biogenesis, cholesterol trafficking, and signal transduction. Cytokine Growth Factor Rev. 2001, 72, 41-51.
32. Williams, T.M.; Sotgia, R; Lee, H.; Hassan, G.; Di Vizio, D.; Bonuc- celli, G.; Capozza, R; Mercier, I.; Rui, H.; Pestell, R.G.; Lisanti, M.R Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. Am J Pathol. 2006, 169, 1784-1801.
33. Sloan, E.K.; Stanley, K.L.; Anderson, R.L. Caveolin-1 inhibits breast cancer growth and metastases. Oncogene 2004,23,7893- 7897.
34. Williams, T.M.; Medina, F; Badano, I.; Hazan, R.B.; Hutchinson, J.; Muller, W.J.; Chopra, N.G.; Scherer, P.E.; Pestell, R.G.; Lisanti, MP. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastases in vivo. Role of cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 2004, 279, 51630-51646.
35. Plenz, G.A.M.; Hofnagel, O.; Robenek, H. Differential modulation of caveolin-1 expression in cells of the vasculature by statins. Circulation 2004, 109, e7-e8.
36. Bonovas, S.; Filioussi, K.; Tsavaris, N.; Sitaras, N.M. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005,23,8606- 8612.
37. Boudreau, D.M.; Yu, O.; Miglioretti, D.L.; Buist, D.S.; Heck- bert, S.R.; Daling, J.R. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarker Prev. 2007, 76,416-421.
38. Pocobelli, G.; Newcomb, P.A.; Trentham-Dietz, A.; Titus-Ernstoff, L; Hampton, J.M.; Egan, K.M. Statin use and risk of breast cancer. Cancer 2008, 772,27-33.
39. Cauley, J.A.; McTiernan, A.; Rodabough, R.J.; LaCroix, A.; Bauer, D.C.; Margolis, K.L.; Paskett, E.D.; Vitolins, M.Z.; Furberg, CD.; Chlebowski, R.T; Women's Health Initiative Research Group. Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst. 2006, 98,700-707.
40. King, B.L.; Love, S.M. The intraductal approach to breast cancer: raison d'etre. Breast Cancer Res. 2006, 8, 206.
41. Dua, R.S.; Isacke, CM.; Gui, J.R The intraductal approach to breast cancer biomarker discovery. J Clin Oncol. 2006,24,1209- 1216.
42. Mannello, R; Tonti, G.A.; Canestari, F. Nutrients and nipple aspirate fluid composition: the breast microenvironment regulates protein expression and cancer etiology. Genes Nutr. 2008, 3,77- 85.
43. Mannello, F; Qin, W.; Zhu, W.; Fabbri, L; Tonti, G.A.; Sauter, E.R. Nipple aspirate fluids from women with breast cancer contain increased levels of group lla secretory phospholipase A2. Breast Cancer Res Treat 2008, 111, 209-218.
44. Duncan, R.E.; El-Sohemy, A.; Arker, M.C Dietary factors and the regulation of 3-hydroxy-3-methylglutaryl Coenzyme A reductase: implications for breast cancer and development. Mol Nutr Food Res. 2005,49,93-100.
45. Kuoppala, J.; Lamminpaa, A.; Pukkala, E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008 (doi: 10.1016/j.ejca.2008. 06.025).